Veraxa Biotech AG - Post De-SPAC annual report, Q4 FY2025

Business Context and Reporting Period

This Shell Company Report on Form 20-F covers Veraxa Biotech Holding AG (PubCo), a Swiss stock corporation formed on June 25, 2025, to effectuate a business combination with Veraxa Biotech AG (the operating company) and Voyager Acquisition Corp. (the SPAC). The business combination was consummated on June 10, 2026. The filing includes audited consolidated financial statements for the operating subsidiary, Veraxa Biotech AG, for the fiscal years ended December 31, 2025, and 2024. Veraxa is an oncology-focused biotechnology company developing antibody drug conjugates (ADCs) and T-cell engagers, with a lead candidate, VX-A901, for acute myeloid leukemia.

Key Financial Metrics

Revenue and Profitability (Veraxa Biotech AG Consolidated)

  • Revenue (2025): CHF 23,426 (Nil in 2024).
  • Net Loss (2025): CHF 66,613,990 (CHF 28,132,971 in 2024).
  • Operating Loss (2025): CHF 66,216,575 (CHF 28,917,881 in 2024).
  • Loss Per Share (2025): CHF (4.60) (CHF (2.00) in 2024).

Cash Flow and Liquidity (Veraxa Biotech AG Consolidated)

  • Cash and Cash Equivalents (Dec 31, 2025): CHF 1,613,989.
  • Net Cash Used in Operating Activities (2025): CHF 9,902,331.
  • Net Working Capital Deficit (Dec 31, 2025): CHF 3,729,227.
  • Accumulated Deficit (Dec 31, 2025): CHF 98,478,340.

Debt and Capitalization (Pro Forma as of Dec 31, 2025)

  • Total Indebtedness: CHF 25,384,000 (includes Senior Secured Note, warrant liabilities, and lease liabilities).
  • Total Shareholders' Equity (Pro Forma): CHF (26,634,000).
  • Outstanding Shares (as of June 10, 2026): 141,407,813 Ordinary Shares and 22,706,305 Warrants.

Material Changes vs. Prior Period

The Company reported a significant increase in net loss of approximately 137% year-over-year, driven primarily by a surge in non-cash stock-based compensation (SBC) expenses.

  • General and Administrative Expenses: Increased by 174% to CHF 46.9 million, largely due to a CHF 27.3 million increase in SBC.
  • Research and Development Expenses: Increased by 63% to CHF 10.3 million, driven by a CHF 3.5 million increase in SBC.
  • Sales and Marketing Expenses: Increased by 91% to CHF 6.9 million, primarily due to SBC.
  • Revenue: The Company generated nominal revenue of CHF 23,426 in 2025 from antibody development projects, compared to nil in 2024.

Guidance, Outlook, and Risks

Recent Financing and Liquidity Outlook

Subsequent to the reporting period, the Company secured significant financing to address liquidity needs:

  • High Trail Capital (HTC) Financing: On June 15, 2026, the Company closed a senior secured note of $27.5 million and a related warrant. The note is 15-month term, amortizing monthly after six months, with payments potentially made in cash or stock.
  • Lincoln Park Capital (LPC) Agreement: A commitment to purchase up to $50.0 million of PubCo Ordinary Shares over 24 months at market-based prices.
  • Going Concern: Management concluded that, considering the HTC and LPC financings, the Company has sufficient liquidity to fund operations for at least the next twelve months.

Risks and Contingencies

  • Material Weakness in Internal Controls: Management identified a material weakness in internal control over financial reporting as of December 31, 2025, related to a lack of controls for complex accounting issues. A remediation plan is in progress.
  • Share-Based Compensation Liability: A significant liability of CHF 71.7 million exists for Share Appreciation Rights (SARs) and Virtual Stock Options, which are remeasured at fair value each period, creating volatility in the income statement.
  • Development Risks: The Company is pre-commercial; success depends on clinical trial outcomes for VX-A901 and other pipeline candidates.

Investor Verification Checklist

  • Verify the terms and amortization schedule of the $27.5 million High Trail Capital senior secured note, specifically the option to pay in stock versus cash.
  • Confirm the status of the remediation plan for the material weakness in internal controls over financial reporting.
  • Review the valuation assumptions used for the CHF 71.7 million SARs liability, as changes in stock price significantly impact reported losses.
  • Monitor the progress of the VX-A901 clinical program for acute myeloid leukemia, as this is the primary value driver.
  • Assess the utilization of the $50 million Lincoln Park Capital purchase agreement and the impact of potential dilution.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.